Background:Alzheimer's disease (AD) is a prevalent neurodegenerative condition characterized
by progressive cognitive decline and memory impairment resulting from the degeneration
and death of brain neurons. Acetylcholinesterase (AChE) inhibitors are used in primary pharmacotherapy
for numerous neurodegenerative conditions, providing their capacity to modulate acetylcholine
levels crucial for cognitive function. Recently, quinazoline derivatives have emerged as a
compelling model for neurodegenerative disease treatment, showcasing promising pharmacological
features. Their unique structural features and pharmacokinetic profiles have sparked interest in their
potential efficacy and safety across diverse neurodegenerative disorders. The exposure of quinazoline
derivatives as a potential therapeutic way underscores the imperative for continued research exploration.
Their multifaceted mechanisms of action and ability to target various pathways implicated
in neurodegeneration offer exciting prospects for developing novel, effective, and well-tolerated
treatments. Further investigations into their pharmacological activities and precise therapeutic roles
are essential to advance our understanding of neurodegenerative disease pathophysiology and promote
the development of modern therapeutic strategies to address this critical medical challenge.Methods:Quinazoline derivatives have gained eminent acetylcholinesterase (AChE) inhibitory activity.
Their ability to effectively modulate AChE activity makes them promising candidates for
treating neurological disorders, particularly Alzheimer's disease (AD). Their intricate molecular
structures confer selectivity and affinity for AChE, offering potential for the development of novel
therapeutic agents targeting cholinergic pathways. Hence, in this study, we designed, synthesized,
and characterized a series of spiro[cycloalakane-1,2'-quinazoline derivatives (1-6) to assess their
possible AChE inhibiting ability using docking into the active sites.Results:The AChE inhibitory potential of spiro[cycloalkane-1,2'-quinazoline derivatives (1-6) was
explored via docking studies of the AChE active site. The findings revealed significant inhibitory
activity and highlighted the promising nature of these derivatives.Conclusion:The synthesized spiro[cycloalkane-1,2'-quinazoline derivatives (1-6) exhibited their
notable potential as AChE inhibitors. The observed significant inhibitory activity suggested that these
derivatives warrant further exploration as candidates for developing therapeutic agents in AChE
inhibitory pathways. This study emphasizes the relevance of quinazoline derivatives in searching for
novel treatments for neurological disorders, particularly associated with cholinergic dysfunction,
and they could be a useful alternative therapeutic agent.